Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ethypharm Iberia Adds NEFOPAM to Portfolio
Details : The deal aims to advance Nefopam HCl, a miscellaneous product, targeting dopamine/serotonin/norepinephrine reuptake.
Product Name : Panagesic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Glibenclamide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glibenclamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2019
Lead Product(s) : Glibenclamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
